Vaxcyte, Inc. — Director's Dealing 2025

Mar 4, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2025-02-27

Reporting Person: GUGGENHIME ANDREW (PRESIDENT AND CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-27	Common Stock	A	22761	—	Acquired	132252	Direct
2025-02-28	Common Stock	F	1270	$73.02	Disposed	130982	Direct
2025-03-03	Common Stock	F	3809	$72.10	Disposed	127173	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-27	Stock Option (right to buy)	$74.22	A	75991	Acquired	2035-02-26	Common Stock (75991)	Direct

Footnotes

F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 7, 2025 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

F2: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

F3: 1/48 of shares subject to the option vest on March 27, 2025, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.